CLEVELAND, July 22, 2013 -- DATATRAK International, Inc. (OTCQX: DTRK), a leader in developing cloud-based, unified eClinical® technologies and delivering related services for the clinical trials industry, today announced CROS NT joined the DATATRAK Connect™ Program. CROS NT is an international Contract Research Organization (CRO) with 21 years of experience in biometrics.
Paolo Morelli, CEO and President, said, "As CROS NT continues to grow, it is becoming increasingly important to offer a broader technology portfolio to our customer base. DATATRAK provides leading-edge technology, coupled with excellent customer service. As such they are a natural fit with our business, and I am pleased we have been able to expand our technology offering through the Partner Program."
"We are pleased to welcome CROS NT into the DATATRAK Connect™ Partner Program," stated Laurence P. Birch,DATATRAK's Chairman of the Board and CEO. "Our DATATRAK ONE™ technology offering will help facilitate their efforts to create a center of excellence for clinical trial data."
The DATATRAK Connect™ Partner Program is a collaboration between synergic companies to accelerate the drug development process. The program allows for extended service offerings to cover all areas of the drug development process with the goal of reducing study costs and furthering business development objectives.
Join DATATRAK Thought Leaders:
Tweet: CROS NT is new DATATRAK Connect™ Partner http://bit.ly/1dOK1Jd
About CROS NT
In its 21st year, CROS NT is an international Contract Research Organization (CRO) specialized in clinical data services. With over 800 studies completed in a variety of therapeutic areas and indications, CROS NT has remained focused on biometrics including statistical consultancy, programming and analysis, clinical data management, medical writing, pharmacovigilance and life science technology solutions. We collect, integrate and analyze data from various sources and use processes and technology to ensure excellent project governance, reporting and traceability. Visit http://www.crosnt.com/ for more information.
DATATRAK International is a worldwide technology and services company delivering unified eClinical® solutions and related services for the clinical trials industry. DATATRAK built its multi-component, comprehensive solution on a single, unified platform and expanded this concept to include services delivery via DATATRAK's Clinical and Consulting Services group. The Company delivers a complete portfolio of software products designed to accelerate the reporting of clinical research data from sites to sponsors and ultimately regulatory authorities, faster and more efficiently than loosely integrated technologies. TheDATATRAK ONE™ software solution, deployed worldwide through an ASP or Enterprise Transfer offering, supports Phase I – Phase IV drug and device studies in multiple languages throughout the world. DATATRAK has offices located in Cleveland, Ohio; Bryan, Texas; and Cary (RTP), North Carolina. For more information, visit http://www.datatrak.net.
Except for the historical information contained in this press release, the statements made in this release are forward-looking statements. These forward-looking statements are made based on management's expectations, assumptions, estimates and current beliefs concerning the operations, future results and prospects of the Company and are subject to uncertainties and factors which are difficult to predict and, in many instances, are beyond the control of the Company, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. For a list of certain factors that may cause actual results to differ materially from those contemplated in these forward looking statements, please see the Company's report filed with the OTCQX Market on May 15, 2013 announcing its results for the first quarter of 2013. The Company undertakes no obligation to update publicly or revise any forward-looking statement whether as a result of new information, future events or otherwise.